 |
|
|
| |
Ledipasvir/Sofosbuvir + Ribavirin for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-World Dataset
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
M Charlton1, MCM Cheung2, M Manns3, N Sajed4, PJF Troke5, J Spellman4, A Copans4, S Arterburn4, DM Brainard4, WL Irving6, HCV Research UK, GR Foster2
1Division of Hepatology and Liver Transplantation, Intermountain Medical Center, Salt Lake City, Utah; 2Liver Unit, Blizard Institute, Queen Mary University of London, London, United Kingdom; 3Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, and German Center of Infection Research (DZIF), Hannover-Braunschweig, Germany; 4Gilead Sciences, Inc., Foster City, California; 5Gilead Sciences Ltd, London, United Kingdom; 6NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham, United Kingdom
|
| |
|
|
|
|
|
